# Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI

> **NCT04338919** · NA · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 2020 (estimated)

## Conditions studied

- Acute Coronary Syndrome
- Percutaneous Coronary Intervention

## Interventions

- **PROCEDURE:** Percutaneous coronary intervention
- **DRUG:** Ticagrelor plus aspirin

## Key facts

- **NCT ID:** NCT04338919
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-14
- **Primary completion:** 2021-04-01
- **Final completion:** 2023-04-01
- **Target enrollment:** 2020 (ESTIMATED)
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04338919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04338919, "Optimized Antiplatelet Therapy on the Prognosis of ACS Patients With Non-predominant Coronary Artery Disease After PCI". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04338919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*